


Birmingham's Institute of Translational Medicine

The DNA revolution has transformed our understanding of the molecular basis of human disease



Watson and Crick solved the structure of DNA in 1953

50+ years investment in basic biomedical research have resulted in the development of a wave of novel potentially highly effective therapies in human disease



Brian Druker



Time Magazine May 2004


The Life Sciences now represents a multi-billion pound industry which the UK is uniquely placed to lead




Requirements for a globally competitive Translational Medicine programme- Birmingham's strengths and challenge

- ✓ High quality clinical teams
- ✓ World class clinical infrastructure
- ✓ One of the largest catchment regions in Europe
- ✓ Strong, translationally focused basic science programme
- ✓ High quality genomics and informatics programmes
- X** Infrastructure optimising clinical trial recruitment

West Midlands Region – the population of Scotland with a profile of the world





CR-UK Institute
Cancer Studies

NHSBT
Cell Immunotherapy
Lab

Wellcome CRF

CCH

UHBFT
New Hospital

MRC Centre for
Immune Regulation

ITM

Advanced Therapies
Facility

Medical School

Trauma HTC

NIHR Centre for Surgical
Reconstruction and
Microbiology

Centre for
Translational
Inflammation Research



Translational research in clinical haematology

Delivering early phase clinical trials to ensure new therapies are safe and work well has traditionally been challenging for many countries – and this means delays to patients getting access to potentially lifesaving new therapies. One project to address this in the UK is a newly built facility for translational research to help patients with leukaemia and other haematological malignancies. The project was Government funded and developed in close collaboration with the Institute of Cancer Studies at Birmingham University. The new Centre for Clinical Haematology has recruited over 400 patients to take part in clinical trials so far, and has leveraged over £15million of free drugs that were not available on the NHS.

D Cameron No 10 Life Sciences Paper 2011

National Trials Acceleration Programme (TAP)

- Core funding for:
 - Central Coordination Hub in Birmingham
 - A funded network of early phase leukaemia centres
- Serving metropolitan areas within the UK-covering catchment area of 20 million
- Dedicated research nurses and data managers

Aims:

- To open four or five new phase I/II haematology trials each year
- To open trials within 6-12 months of award letter
- To complete, analyse and publish the results of each trial no more than two years after recruitment of the first patient



TAP
From Leukaemia &
Lymphoma Research

Strategy for UK Life Sciences One Year On

 HM Government

Industrial Strategy: government and industry in partnership



Strategy for UK Life Sciences

One Year On

The Trials Acceleration Programme (TAP) by Leukaemia & Lymphoma Research is designed to give haematological oncology patients accelerated and wider access to early stage trials. Working within the existing NIHR Cancer Research Network, TAP's dedicated centralised management at the University of Birmingham minimises the 'red tape' to establish trials and deliver accelerated results via disseminated patient recruitment across 13 UK centres. Early results from Novartis Pharmaceuticals UK Ltd show a 50% reduction in set-up time and significant reduction in costs per patient. In its first year of operation TAP has ratified nine new trials that would not otherwise have taken place in the UK including collaborations with eight pharmaceutical companies.

Delivered by



Birmingham
Health
Partners



Institute of
Translational
Medicine
Birmingham

The Birmingham Institute of Translational Medicine: Progress to Date

- £24 million ITM announced by Government within £1 billion City Deal in recognition of Birmingham's strategic strengths in the Life Sciences
- Will fund a five story building which co-locates all the key components of an effective translational infrastructure
- 3 floors with dedicated office space for key clinical academic specialities
- 1 floor housing a dedicated Cancer Unit, containing office space for cancer specialties and a link to the Birmingham Cancer Trials Unit
- 1 floor dedicated to stratified medicine in oncology and non-malignant disease and health economic appraisal unit
- Commercial business hub for SMEs/pharma/biotech
- Will generate more than £100 million free drugs and in excess of 600 jobs

Strategy for UK Life Sciences One Year On

 HM Government

Industrial Strategy: government and industry in partnership



Strategy for UK Life Sciences

One Year On

The **new £24m Birmingham Institute of Translational Medicine**, funded in part through the **Greater Birmingham and Solihull City Deal** will rapidly accelerate the development of new therapies, providing capacity for high quality clinical trial design and delivery, and bringing together clinicians, academics, small and medium-sized enterprises (SMEs) and large pharmaceutical firms under one roof.

ITM Front Entrance



The Birmingham Institute of Translational Medicine

- April 2014 External review conducted by Deloitte Monitor:
Exceptional agglomeration of strategic strengths in the Life Sciences
Distinct value proposition in:
 - academic led clinical trials
 - co-producing commercial trials
 - stratified medicine
 - urgent requirement for medical leadership, talent retention and commercial focus
- Search for ITM Director of international calibre
- June 2014 Birmingham City Council Purchase of Battery Park
- June 2014 LEP Inaugural Life Sciences Advisory Board

The Birmingham Institute of Translational Medicine

- Aug 2014 £7 million MRC stratified medicine grant to ITM
- Sept 2014 Discussion with Birmingham Business School to develop ITM Commercial Director
- Identification of potential synergies with Birmingham Drug Discovery programme
- Discussion with LEP concerning maximisation of future commercial impact of ITM